BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 252 filers reported holding BLUEBIRD BIO INC in Q1 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $674,922 | -8.2% | 685,757 | +19.4% | 0.00% | – |
Q1 2024 | $734,953 | +26.7% | 574,183 | +36.6% | 0.00% | – |
Q4 2023 | $579,936 | -53.6% | 420,244 | +2.1% | 0.00% | – |
Q3 2023 | $1,250,857 | -6.2% | 411,466 | +1.5% | 0.00% | – |
Q2 2023 | $1,333,838 | +5.2% | 405,422 | +1.7% | 0.00% | – |
Q1 2023 | $1,267,484 | -47.3% | 398,580 | +14.6% | 0.00% | -100.0% |
Q4 2022 | $2,406,904 | +17.6% | 347,819 | +7.5% | 0.00% | – |
Q3 2022 | $2,047,000 | +66.2% | 323,492 | +8.6% | 0.00% | – |
Q2 2022 | $1,232,000 | -6.9% | 297,912 | +9.2% | 0.00% | – |
Q1 2022 | $1,324,000 | -50.9% | 272,903 | +1.1% | 0.00% | – |
Q4 2021 | $2,696,000 | -57.7% | 269,935 | -19.0% | 0.00% | -100.0% |
Q3 2021 | $6,372,000 | -36.7% | 333,456 | +5.9% | 0.00% | -50.0% |
Q2 2021 | $10,072,000 | +49.5% | 314,956 | +40.9% | 0.00% | +100.0% |
Q1 2021 | $6,737,000 | -35.8% | 223,453 | -7.9% | 0.00% | -50.0% |
Q4 2020 | $10,500,000 | -21.2% | 242,655 | -1.8% | 0.00% | -33.3% |
Q3 2020 | $13,333,000 | -13.1% | 247,127 | -1.6% | 0.00% | -25.0% |
Q2 2020 | $15,336,000 | +66.9% | 251,236 | +25.6% | 0.00% | +33.3% |
Q1 2020 | $9,191,000 | -49.4% | 199,976 | -3.4% | 0.00% | -40.0% |
Q4 2019 | $18,157,000 | -6.1% | 206,911 | -1.7% | 0.01% | 0.0% |
Q3 2019 | $19,334,000 | -26.5% | 210,574 | +1.9% | 0.01% | -28.6% |
Q2 2019 | $26,296,000 | -22.1% | 206,728 | -3.6% | 0.01% | -22.2% |
Q1 2019 | $33,739,000 | +50.8% | 214,450 | -4.9% | 0.01% | +28.6% |
Q4 2018 | $22,366,000 | -73.7% | 225,455 | -61.2% | 0.01% | -68.2% |
Q3 2018 | $84,926,000 | +73.1% | 581,695 | +86.1% | 0.02% | +69.2% |
Q2 2018 | $49,064,000 | -19.9% | 312,621 | -12.8% | 0.01% | -23.5% |
Q1 2018 | $61,234,000 | +5.3% | 358,619 | +9.9% | 0.02% | +13.3% |
Q4 2017 | $58,141,000 | +72.4% | 326,446 | +32.9% | 0.02% | +66.7% |
Q3 2017 | $33,729,000 | +40.7% | 245,563 | +7.6% | 0.01% | +28.6% |
Q2 2017 | $23,964,000 | +15.3% | 228,114 | -0.2% | 0.01% | +16.7% |
Q1 2017 | $20,787,000 | +63.0% | 228,663 | +10.7% | 0.01% | +50.0% |
Q4 2016 | $12,751,000 | -3.5% | 206,652 | +6.0% | 0.00% | 0.0% |
Q3 2016 | $13,215,000 | +82.6% | 194,978 | +16.6% | 0.00% | +100.0% |
Q2 2016 | $7,239,000 | +10.5% | 167,217 | +8.5% | 0.00% | 0.0% |
Q1 2016 | $6,552,000 | -31.7% | 154,155 | +3.3% | 0.00% | -33.3% |
Q4 2015 | $9,587,000 | -29.0% | 149,263 | -5.4% | 0.00% | -25.0% |
Q3 2015 | $13,494,000 | -50.6% | 157,735 | -2.7% | 0.00% | -50.0% |
Q2 2015 | $27,297,000 | +38.1% | 162,133 | -0.9% | 0.01% | +60.0% |
Q1 2015 | $19,763,000 | +68.4% | 163,641 | +27.9% | 0.01% | +66.7% |
Q4 2014 | $11,737,000 | +194.9% | 127,976 | +15.4% | 0.00% | +200.0% |
Q3 2014 | $3,980,000 | -32.8% | 110,917 | -27.8% | 0.00% | 0.0% |
Q2 2014 | $5,922,000 | +748.4% | 153,536 | +400.0% | 0.00% | – |
Q1 2014 | $698,000 | +19.1% | 30,710 | +9.9% | 0.00% | – |
Q4 2013 | $586,000 | -37.7% | 27,942 | -20.0% | 0.00% | – |
Q3 2013 | $940,000 | – | 34,908 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 1,964,000 | $59,215,000 | 1.36% |
Birchview Capital, LP | 75,500 | $2,276,000 | 1.35% |
Camber Capital Management LP | 1,000,000 | $30,150,000 | 1.04% |
Sessa Capital IM, L.P. | 875,000 | $26,381,000 | 1.02% |
Bain Capital Life Sciences Investors, LLC | 538,179 | $16,226,000 | 0.92% |
Tarsadia Capital, LLC | 100,000 | $3,015,000 | 0.81% |
Bullseye Asset Management LLC | 67,872 | $2,046,000 | 0.76% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,304,246 | $39,323,000 | 0.58% |
MANGROVE PARTNERS IM, LLC | 175,178 | $5,282,000 | 0.53% |
Parametrica Management Ltd | 37,712 | $1,080,000 | 0.52% |